Clinical Utility (CU) Evaluation of the Health-Related Quality-of-Life (HRQoL) QLQ-GINET21 Questionnaire (QNR) in the Treatment of Patients (pts) with Gastrointestinal (GI) Neuroendocrine Tumors (NETs). QUALINETS Study

#2146

Introduction: QLQ-GINET21 for pts with GI-NETs covers muscle/bone pain, body image, information, sexual function, symptoms, social function and disease-related concerns.

Aim(s): To assess QLQ-GINET21 CU for clinical and therapeutic decisions in practice.

Materials and methods: In non-interventional QUALINETS (NCT02853422), 36 specialists completed an ad hoc survey to assess QLQ-GINET21 CU in pts with GI-NETs who completed QLQ-C30 and QLQ-GINET21. Items were rated 0 to 4; CU was scored low/moderate/high (primary endpoint: % pts) in 3 dimensions: a) therapeutic and clinical decisions (7 items: 0¬–9/10–19/20–28); b) doctor–patient communication (3 items: 0–4/5–8/9–12); and c) QNR characteristics (4 items: 0–5/6–11/12–16). HRQoL and relationships between CU, QNR scores, health status (HS) and clinical variables were investigated (ANOVA for categorical variables).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Gallego J, Reig O, Sastre J, Garcia I, Segura A,

Keywords: neuroendocrine tumors, Quality of Life, QLQ-GINET21, utility,